Bülbül Hale, Nazlı Hamza Ekmel, Olgun Aybüke, Togay Alper, Kahraman Dudu Solakoğlu
Hematology Department, Tepecik Training and Research Hospital, Yenisehir, Konak/İzmir, Turkey.
Internal Medicine Department, Tepecik Training and Research Hospital, Yenisehir, Konak/İzmir, Turkey.
Leuk Res Rep. 2022;18:100336. doi: 10.1016/j.lrr.2022.100336. Epub 2022 Jun 30.
Although novel therapies have improved the treatment outcome of patients, chronic lymphocytic leukaemia (CLL) is still considered incurable. Recently, a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), causing coronavirus disease 2019 (Covid 19), emerged in late 2019, and it has posed a global health threat. In a limited number of cases, it has been shown that some lymphoma types spontaneously regress after SARS-CoV2 infection suggesting that the infection can trigger de immune system against the tumour cell. Cross-reactivity of pathogen-specific T cells with tumour antigens and natural killer cell activation can be the possible mechanism of this hypothesis.
尽管新型疗法改善了患者的治疗效果,但慢性淋巴细胞白血病(CLL)仍被认为无法治愈。最近,一种新型冠状病毒,即严重急性呼吸综合征冠状病毒2(SARS-CoV2),于2019年末出现,并引发了2019冠状病毒病(Covid-19),对全球健康构成了威胁。在少数病例中,已表明某些淋巴瘤类型在感染SARS-CoV2后会自发消退,这表明该感染可触发针对肿瘤细胞的免疫系统。病原体特异性T细胞与肿瘤抗原的交叉反应以及自然杀伤细胞的激活可能是这一假说的潜在机制。